The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Comedian Nikki Glaser, host of the 2025 Golden Globe Awards ceremony, dove right in at the start of her opening monologue: ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Investment group Atlas Ventures has closed its fourteenth fund, raising $450 million for the next round of investment ... of incretin therapies like Novo Nordisk's Wegovy (semaglutide) and Eli ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK725.00. The company’s shares closed ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,000.00. The company’s shares closed last Friday ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...